Skip to Content

Clorazepate Dipotassium

Class: Benzodiazepines
VA Class: CN302
Molecular Formula: C16H11ClK2N2O4
CAS Number: 57109-90-7
Brands: GenXene, Tranxene

Medically reviewed on November 13, 2017

Warning

    Concomitant Use with Opiates
  • Concomitant use of benzodiazepines and opiates may result in profound sedation, respiratory depression, coma, and death.700 701 703 705 706 707

  • Reserve concomitant use for patients in whom alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy and monitor closely for respiratory depression and sedation.700 703 (See Specific Drugs under Interactions.)

Introduction

Benzodiazepine.a b c Anxiolytic, sedative, anticonvulsant.a b c

Uses for Clorazepate Dipotassium

Alcohol Withdrawal

Relief of agitation and tremor and prevention or symptomatic relief of delirium tremens and hallucinations associated with acute alcohol withdrawal.a b c

Anxiety Disorders

Management of anxiety disorders and short-term relief of symptoms of anxiety.a b c

Seizure Disorders

Has been used as an adjunct to other anticonvulsants in the prophylactic management of partial seizures.a b c

Clorazepate Dipotassium Dosage and Administration

General

  • Use the smallest effective dose (especially in geriatric or debilitated patients and in those with liver disease or low serum albumin) to avoid oversedation.a b

  • Consider the long elimination half-life of clorazepate’s metabolites when making dosage adjustments.a b (See Half-life under Pharmacokinetics.)

  • In patients who have received prolonged (e.g., for several months) therapy, avoid abrupt discontinuance, since manifestations of withdrawal can be precipitated; gradually taper dosage.a b c

Anxiety

  • Periodically reassess the usefulness of the drug.a b c Efficacy beyond 4 months not systematically evaluated.a b c Administer for the shortest possible period of time; frequent dosage adjustments may be required.b

Seizures

  • Do not discontinue clorazepate abruptly in patients with a history of seizure disorder, since seizures may be precipitated.a b

Administration

Oral Administration

Administer orally in 1–4 doses daily.a

Dispensing Considerations

Do not remove desiccant packets from original container.a Consider use of desiccant packets when dispensing a large number of tablets in a multidose container.a In the presence of moisture, carbon dioxide may form, resulting in rapid tablet disintegration.a

Dosage

Available as clorazepate dipotassium; dosage expressed in terms of the salt.c

Pediatric Patients

Seizure Disorders
Adjunctive Therapy for Partial Seizures
Oral

Children 9–12 years of age: Initially, 7.5 mg twice daily; increase daily dosage by no more than 7.5 mg at weekly intervals.a c Do not exceed 60 mg daily.a c

Children >12 years of age: Initially, 7.5 mg 3 times daily; increase daily dosage by no more than 7.5 mg at weekly intervals.a c Do not exceed 90 mg daily.a c

Adults

Alcohol Withdrawal
Oral

Day 1: 30 mg initially, followed by an additional 30–60 mg in divided doses; not to exceed 90 mg daily.a c

Day 2: 45–90 mg in divided doses.a c

Day 3: 22.5–45 mg in divided doses.a c

Day 4: 15–30 mg in divided doses.a c

Gradually reduce dosage to 7.5–15 mg daily; discontinue when patient’s condition is stable.a c

Anxiety Disorders
Oral

Usual dosage: 30 mg daily in divided doses.a c

Alternatively, administer a single daily dose at bedtime.a c Initial dosage: 15 mg at bedtime.a c

Gradually adjust dosage to 15–60 mg daily.a c

Seizure Disorders
Adjunctive Therapy for Partial Seizures
Oral

Initially, 7.5 mg 3 times daily; increase daily dosage by no more than 7.5 mg at weekly intervals.a c Do not exceed 90 mg daily.a c

Prescribing Limits

Pediatric Patients

Seizure Disorders
Adjunctive Therapy for Partial Seizures
Oral

Children 9–12 years of age: Maximum 60 mg daily.a c

Children >12 years of age: Maximum 90 mg daily.a c

Adults

Alcohol Withdrawal
Oral

Maximum 90 mg daily.a c

Seizure Disorders
Adjunctive Therapy for Partial Seizures
Oral

Maximum 90 mg daily.a c

Special Populations

Hepatic Impairment

Reduce dosage.b Use smallest effective dosage.a

Renal Impairment

No specific dosage recommendations.c

Geriatric or Debilitated Patients

Reduce initial dosage.c Adjust dosage gradually, with careful monitoring, to avoid oversedation.c

Anxiety Disorders

Initially, 7.5–15 mg daily in divided doses or as a single bedtime dose.a c

Cautions for Clorazepate Dipotassium

Contraindications

  • Known hypersensitivity to clorazepate.c

  • Many manufacturers state that benzodiazepines (including clorazepate) are contraindicated in patients with acute angle-closure glaucoma but may be administered to patients with open-angle glaucoma who are receiving appropriate therapy;b c however, clinical rationale for this contraindication has been questioned.b

Warnings/Precautions

Warnings

Concomitant Use with Opiates

Concomitant use of benzodiazepines, including clorazepate, and opiates may result in profound sedation, respiratory depression, coma, and death.700 701 703 705 706 707 Substantial proportion of fatal opiate overdoses involve concurrent benzodiazepine use.700 701 705 706 707 711

Reserve concomitant use of clorazepate and opiates for patients in whom alternative treatment options are inadequate.700 703 (See Specific Drugs under Interactions.)

CNS Effects

Performance of activities requiring mental alertness and physical coordination may be impaired.b c

Concurrent use of other CNS depressants may cause additive or potentiated CNS depression.b c (See Concomitant Use with Opiates under Cautions and also see Specific Drugs under Interactions.)

Psychiatric Indications

Avoid use in patients with depressive neuroses or psychotic reactions in which anxiety is not prominent.b c

Abuse Potential

Possible tolerance, psychologic dependence, and physical dependence following prolonged use.b c

Patients with a history of drug or alcohol dependence or abuse are at risk of habituation or dependence; benzodiazepines generally should be used only with careful surveillance in such patients.c e f

Withdrawal Syndrome

Abrupt discontinuance may result in symptoms of withdrawal (similar to barbiturates).b c Symptoms may be relieved by tapering the dosage.b c

Fetal/Neonatal Morbidity

Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, meprobamate) during the first trimester of pregnancy.b c Since use of anxiolytics is rarely urgent, their use during the first trimester almost always should be avoided.b c

General Precautions

Suicide

Use with caution in depressed patients; potential for suicidal tendencies.b c Prescribe and dispense drug in the smallest feasible quantity.b c

Laboratory Testing

Monitor blood counts and liver function tests periodically during prolonged therapy.b c

Specific Populations

Pregnancy

Category D.d (See Fetal/Neonatal Morbidity under Cautions.)

Lactation

Metabolite of clorazepate, desmethyldiazepam, is distributed into milk.c Discontinue nursing or the drug.c

Pediatric Use

Safety and efficacy not established in children <9 years of age.a c

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.c Possibility of greater sensitivity to the drug in some geriatric individuals.c

Use reduced initial dosage because of potential for greater sensitivity to the drug and because of greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease and drug therapy observed in the elderly.c (See Geriatric Patients under Dosage and Administration.) Monitor closely.c

Hepatic Impairment

Use with caution.b c

Renal Impairment

Use with caution.b c

Common Adverse Effects

Drowsiness,b c dizziness,b c nervousness,c blurred vision,b c dry mouth,b c headache,b c confusion,b c GI complaints.b c

Interactions for Clorazepate Dipotassium

Specific Drugs

Drug

Interaction

Comments

Antacids

Possible decrease in rate and extent of conversion of clorazepate to desmethyldiazepam;b however, manufacturer states that usual antacid dosages do not substantially alter clorazepate bioavailabilityc

Cimetidine

Decreased plasma clearance and increased plasma half-lives and concentrations of the benzodiazepine200 202 203 204 205 206 207 372 506 507

Clinical importance not well established;200 206 506 507 consider possible need for clorazepate dosage reduction200 372 610

CNS depressants (e.g., alcohol, anticonvulsants, antidepressants, barbiturates, hypnotics, phenothiazines)

Additive CNS depressionb c

Use with caution to avoid overdosageb c

Avoid alcohol use700

Disulfiram

Possible inhibition of clorazepate metabolism200

Use with caution; consider possible need for clorazepate dosage reduction200

HIV protease inhibitors (e.g., fosamprenavir, ritonavir, saquinavir)

Possible increased benzodiazepine concentrations614 620 622

Clinical importance not established; consider possible need for clorazepate dosage reduction614 620 622

Opiate agonists and partial agonists

Risk of profound sedation, respiratory depression, coma, or death700 701 703 705 706 707

Whenever possible, avoid concomitant use708 709 710 711

Opiate analgesics: Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy; monitor closely for respiratory depression and sedation700 703

In patients receiving clorazepate, initiate opiate analgesic, if required, at reduced dosage and titrate based on clinical response700 713

In patients receiving an opiate analgesic, initiate clorazepate at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response713

Opiate antitussives: Avoid concomitant use700 704

Consider offering naloxone to patients receiving benzodiazepines and opiates concomitantly709 712

Clorazepate Dipotassium Pharmacokinetics

Absorption

Bioavailability

Rapidly decarboxylated in the GI tract and absorbed as desmethyldiazepam (nordiazepam).b c Rate of decarboxylation decreases as gastric pH increases.b

Distribution

Extent

Benzodiazepines are widely distributed into body tissues and cross the blood-brain barrier.b

Desmethyldiazepam is distributed into milk.c

Benzodiazepines and their metabolites generally cross the placenta.b

Plasma Protein Binding

Desmethyldiazepam: 97–98%.b c

Elimination

Metabolism

Rapidly decarboxylated in the GI tract to form desmethyldiazepam;b c further metabolized in the liver via hydroxylation and subsequent conjugation with glucuronic acid.b c g g Major active metabolites are desmethyldiazepam and oxazepam.b

Elimination Route

Excreted principally in urine.b c

Half-life

Metabolites: Desmethyldiazepam: 40–50 hours (range: 30–200 hours).b c Oxazepam: 3–21 hours.b

Special Populations

In geriatric patients and patients with liver disease, half-life of desmethyldiazepam may be prolonged.b

Benzodiazepines are not appreciably removed by hemodialysis.b

Stability

Storage

Oral

Tablets

Tight, light-resistant containers at <25°C.c

Protect from moisture.c In the presence of moisture, carbon dioxide may form, resulting in rapid tablet disintegration.a Do not remove desiccant packets from drug container.a

Actions

  • Effects appear to be mediated through the inhibitory neurotransmitter GABA; the site and mechanism of action within the CNS appear to involve a macromolecular complex (GABAA-receptor-chloride ionophore complex) that includes GABAA receptors, high-affinity benzodiazepine receptors, and chloride channels.320 358 359 360 361 362 363 364 365 366 367 368 369 370

Advice to Patients

  • Risk of potentially fatal additive effects (e.g., profound sedation, respiratory depression, coma) if used concomitantly with opiates either therapeutically or illicitly.700 703 Avoid concomitant use of opiate antitussives;700 704 also avoid concomitant use of opiate analgesics unless use is supervised by clinician.700 703

  • Potential for drug to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.b c

  • Importance of informing clinicians of any behavioral or mental changes, memory impairment, tolerance, or dependence/withdrawal symptoms.b c

  • Importance of taking only as prescribed; do not increase dosage or duration of therapy or abruptly discontinue drug unless otherwise instructed by a clinician.b c

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.b c Importance of not consuming alcoholic beverages.c

  • Importance of informing clinicians about any concomitant illnesses, particularly depression.c

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.b c

  • Importance of informing patients of other important precautionary information.b c (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Clorazepate Dipotassium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

3.75 mg*

Clorazepate Dipotassium Tablets ( C-IV; scored)

GenXene ( C-IV; scored)

Alra

7.5 mg*

Clorazepate Dipotassium Tablets ( C-IV; scored)

GenXene ( C-IV; scored)

Alra

Tranxene T-TAB ( C-IV; scored)

Recordati

15 mg*

Clorazepate Dipotassium Tablets ( C-IV; scored)

GenXene ( C-IV; scored)

Alra

AHFS DI Essentials. © Copyright 2018, Selected Revisions November 13, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

200. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger; 1985:276-7, 393-4.

202. Klotz U, Reimann I. Delayed clearance of diazepam due to cimetidine. N Engl J Med. 1980; 302:1012-4. http://www.ncbi.nlm.nih.gov/pubmed/6767973?dopt=AbstractPlus

203. Desmond PV, Patwardhan RV, Schenker S et al. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980; 93:266-8. http://www.ncbi.nlm.nih.gov/pubmed/7406377?dopt=AbstractPlus

204. Gough PA, Curry SH, Araujo OE et al. Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. Br J Clin Pharmacol. 1982; 14:739-42. http://www.ncbi.nlm.nih.gov/pubmed/7138754?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1427494&blobtype=pdf

205. Ruffalo RL, Thompson JF, Segal J. Cimetidine-benzodiazepine drug interaction. Am J Hosp Pharm. 1981; 38:1365-6. http://www.ncbi.nlm.nih.gov/pubmed/6116430?dopt=AbstractPlus

206. Klotz U, Reimann I. Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther. 1981; 30:513-7. http://www.ncbi.nlm.nih.gov/pubmed/7285485?dopt=AbstractPlus

207. Pharmacia & Upjohn. Halcion (triazolam) tablets prescribing information (dated 1993 Jul). In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2093-5.

320. Rall TW. Hypnotics and sedatives; ethanol: benzodiazepines and management of insomnia. In: Gilman AG, Rall TW, Nies AS et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:346-58,369-70.

358. Bloom FE. Neurohumoral transmission and the central nervous system: amino acids. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:256-8.

359. Haefely W. The GABA-benzodiazepine interaction fifteen years later. Neurochem Res. 1990; 15:169-74. http://www.ncbi.nlm.nih.gov/pubmed/2159122?dopt=AbstractPlus

360. De Feudis FV. Overview—GABAa receptors. Ann NY Acad Sci. 1990; 585:231-40. http://www.ncbi.nlm.nih.gov/pubmed/2162643?dopt=AbstractPlus

361. Mohler H, Malherbe P, Draguhn A et al. GABAa-receptors: structural requirements and sites of gene expression in mammalian brain. Neurochem Res. 1990; 15:199-207. http://www.ncbi.nlm.nih.gov/pubmed/2159125?dopt=AbstractPlus

362. Farrant M, Gibbs TT, Farb DH. Molecular and cellular mechanisms of GABA/benzodiazepine-receptor regulation: electrophysiological and biochemical studies. Neurochem Res. 1990; 15:175-91. http://www.ncbi.nlm.nih.gov/pubmed/2159123?dopt=AbstractPlus

363. Sieghart W. Benzodiazepine receptor subtypes and their possible clinical significance. Psychopharmacol Ser. 1989; 7:131-7. http://www.ncbi.nlm.nih.gov/pubmed/2574448?dopt=AbstractPlus

364. Knapp RJ, Malatynska E, Yamamura HI. From binding studies to the molecular biology of GABA receptors. Neurochem Res. 1990; 15:105-12. http://www.ncbi.nlm.nih.gov/pubmed/2159117?dopt=AbstractPlus

365. Williams M. Anxioselective anxiolytics. J Med Chem. 1983; 26:619-28. http://www.ncbi.nlm.nih.gov/pubmed/6132997?dopt=AbstractPlus

366. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990; 42:223-86. http://www.ncbi.nlm.nih.gov/pubmed/2217531?dopt=AbstractPlus

367. Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci. 1989; 238:294-301. http://www.ncbi.nlm.nih.gov/pubmed/2569974?dopt=AbstractPlus

368. Haefely WE. Benzodiazepines. Int Anesthesiol Clin. 1988; 26:262-72. http://www.ncbi.nlm.nih.gov/pubmed/2461909?dopt=AbstractPlus

369. Schoch P, Richards JG, Haring P et al. Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature. 1985; 314:168-71. http://www.ncbi.nlm.nih.gov/pubmed/2983231?dopt=AbstractPlus

370. Haefely W. Endogenous ligands of the benzodiazepine receptor. Pharmacopsychiatry. 1988; 21:43-6. http://www.ncbi.nlm.nih.gov/pubmed/2834760?dopt=AbstractPlus

372. Pfizer. Xanax (alprazolam) prescribing information. New York, NY; 2006 Mar.

506. Roche Laboratories. Versed (midazolam hydrochloride) prescribing information. Nutley, NJ: 1998 Oct.

507. Klotz U, Aruela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985; 38:652-5. http://www.ncbi.nlm.nih.gov/pubmed/2933205?dopt=AbstractPlus

610. Pharmacia & Upjohn Company. Halcion (triazolam) tablets prescribing information. Kalamazoo, MI; 2003 Jan.

614. Roche Laboratories. Invirase (saquinavir mesylate) capsules prescribing information. Nutley, NJ; 2005 Sep.

620. Abbott Laboratories. Norvir (ritonavir) soft gelatin capsules and oral solution prescribing information. North Chicago, IL; 2006 Jan.

622. GlaxoSmithKline. Lexiva (fosamprenavir calcium) tablets prescribing information. Research Triangle Park, NC; 2006 June.

700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website. https://www.fda.gov/drugs/drugsafety/ucm518473.htm

701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309:657-9. http://www.ncbi.nlm.nih.gov/pubmed/23423407?dopt=AbstractPlus

703. Hughes A. Letter to manufacturers of benzodiazepines: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518615.pdf

704. Seymour S. Letter to manufacturers of opioid antitussives: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518612.pdf

705. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698. http://www.ncbi.nlm.nih.gov/pubmed/26063215?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4462713&blobtype=pdf

706. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015; 49:493-501. http://www.ncbi.nlm.nih.gov/pubmed/26143953?dopt=AbstractPlus

707. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016; 17:85-98. http://www.ncbi.nlm.nih.gov/pubmed/26333030?dopt=AbstractPlus

708. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38-47. http://www.ncbi.nlm.nih.gov/pubmed/24217469?dopt=AbstractPlus

709. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65:1-49. http://www.ncbi.nlm.nih.gov/pubmed/26987082?dopt=AbstractPlus

710. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116.

711. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan. http://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf

712. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf

713. Recordati Rare Diseases, Inc. Tranxene T-TAB (clorazepate dipotassium) tablets prescribing information. Lebanon, NJ; 2016 Sep.

a. AHFS drug information 2008. McEvoy GK, ed. Clorazepate dipotassium. Bethesda, MD: American Society of Health-System Pharmacists; 2008:2583-4.

b. AHFS drug information 2008. McEvoy GK, ed. Benzodiazepines general statement. Bethesda, MD: American Society of Health-System Pharmacists, 2008:2571-80.

c. Ovation Pharmaceuticals, Inc. Tranxene T-TAB, Tranxexe- SD, and Tranxene-SD Half Strength (clorazepate dipotassium) tablets prescribing information. Deerfield, IL; 2005 Apr.

d. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Baltimore, MD: Williams & Wilkins; 2005:358-9.

e. Sandoz. Oxazepam capsules prescribing information. Princeton, NJ; 2007 Nov.

f. Valeant. Librium (chlordiazepoxide hydrochloride) capsules prescribing information. Costa Mesa, CA; 2005 Jul

g. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacologic basis of therapeutics. 11th ed. New York; McGraw-Hill; 2006:401-28.

Hide